Blink Charging Surpasses 100,000 Charger Milestone
Blink’s charging solutions have empowered drivers, hosts, and fleets to transition smoothly to electric transportation, contributing to EV charging infrastructure […]
StepStone Group Completes Fundraising for Fifth Private Equity Secondaries Program at $7.4 billion
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on […]
SEALSQ Research Receives Recognition at CRYPTOLOGY2024 for Post-Quantum Work
Geneva, Switzerland, Sept. 27, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on […]
Hurco Celebrates Successful IMTS as Show Generates Excitement Over Technological Advancements
INDIANAPOLIS, Sept. 27, 2024 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) delivered a standout performance at the 2024 International […]
Lifetime Brands Inc. Grows Commercial Food Services Business with Expansion of its Mikasa Hospitality Portfolio
Secures Agreement with Premium Glassware Brands Royal Leerdam® and ONIS® Adds Scale to Commercial Food Services Business GARDEN CITY, N.Y., […]
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and […]
Join Nova Minerals’ Exclusive Live Investor Webinar and Q&A Session on October 7
Caulfield, Australia, Sept. 27, 2024 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3), […]
VEON Bonds to Re-Enter CEMBI and JACI Indices
Amsterdam, 27 September 2024 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and […]
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong […]
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of […]
